PETACH TIKVA, Israel — Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced it received a Notice of Allowance from the Canadian Intellectual Property Office for its patent application titled “An A3 Adenosine Receptor...
treatment News
TORONTO, Canada – Biogen Canada Inc. is encouraged by the recent Health Technology Assessment (HTA) evaluations issued by Canada’s Drug Agency (CDA) and the Institut national d’excellence en santé et en services sociaux (INESSS) for QALSODY™ (tofersen injection), the first therapy designed to target a known genetic cause of amyotrophic lateral sclerosis (ALS). CDA Issues Positive Reimbursement...
BEIJING & CAMBRIDGE, Mass. – CANbridge Pharmaceuticals Inc., a leading China-based global rare disease-focused biopharmaceutical company committed to the research, development and commercialization of transformative therapies, announced that the Chinese National Medical Products Administration (NMPA) has approved an Investigational New Drug (IND) application for CAN106, a long-acting humanized monoclonal antibody...
Berlin, Germany – The team at Charité – Universitätsmedizin Berlin is astounded by the huge improvement seen in a female patient with severe systemic lupus erythematosus (SLE) after being treated with the cancer medication teclistamab. Not long ago, the 23-year-old was wheelchair-bound due to the autoimmune disease. Nearly six months...
Turku, Finland – Researchers at the University of Turku, have uncovered how the new bexmarilimab therapy alters the function of immune cells so that they can infiltrate the tumor in cancer patients who do not respond to any other current therapies. Cancer immunotherapy utilizes the body’s own defense machinery, the...
Düsseldorf, Germany – A recent case report from Germany highlights the potential of blinatumomab, a cancer therapy, in treating refractory generalized myasthenia gravis (gMG)— a form of the autoimmune disease that does not respond to standard treatments. Two women with severe, treatment-resistant MG experienced marked clinical improvements following treatment with...
San Antonio, Texas – A promising new cancer therapy also appears extremely potent against one of the world’s most devastating infectious diseases: tuberculosis (TB). Scientists at Texas Biomedical Research Institute (Texas Biomed) found the therapy dramatically reduces TB growth, even for bacteria that are drug-resistant. The findings, reported in the journal...
ATLANTA – Cancer Treatment Centers of America® (CTCA) Atlanta has launched its Women’s Cancer Center, led by an experienced roster of fellowship-trained, board-certified physicians and clinicians with expertise in breast and gynecologic oncology. The center offers comprehensive cancer care – from screenings, diagnostic evaluations and treatment plans to supportive care...
NEEDHAM, Mass. — Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer, today announced the presentation of updated data from an ongoing phase 1b clinical trial of its herpes simplex virus-1 (HSV-1) replication-competent viral immunotherapy candidate, CAN-3110,...
NEEDHAM, Mass. — Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the European Medicines Agency (EMA) has granted Orphan Designation for CAN-2409 (aglatimagene besadenovec) for the treatment of pancreatic cancer. This...